Nohla Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Out of Business
  • Employees
  • 43
Employees
  • Latest Deal Type
  • Out of Business

Nohla Therapeutics General Information

Description

Developer of universal, off-the-shelf cell therapies intended to help treat hematologic malignancies and other critical diseases. The company's products are based on a unique umbilical cord blood expansion platform, providing doctors the functional support of bone marrow in response to each patient's unique blood-production needs, without any requirement for HLA matching.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 1600 Fairview Avenue East
  • Suite 100
  • Seattle, WA 98102
  • United States
+1 (206) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Nohla Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 01-Nov-2019 00000 Completed Out of Business
4. Early Stage VC (Series B) 12-Jul-2018 0000 00000 Completed Clinical Trials - Phase 2
3. Grant 28-Sep-2017 00.00 000.00 Completed Startup
2. Early Stage VC (Series A) 29-Nov-2016 $43.5M $64.5M 00000 Completed Startup
1. Corporate 24-Dec-2015 $21M $21M Completed Startup
To view Nohla Therapeutics’s complete valuation and funding history, request access »

Nohla Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 000,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A1 000,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.00
To view Nohla Therapeutics’s complete cap table history, request access »

Nohla Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of universal, off-the-shelf cell therapies intended to help treat hematologic malignancies and other critical
Biotechnology
Seattle, WA
43 As of 2018
00000
00000000 00 00000

00 00000

inim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis
0000000000000
Glasgow, United Kingdom
00 As of 0000
000.00
0000 0000-00-00
0000000000 0 000.00

000000 0

dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore ma
0000000000000
Cambridge, MA
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nohla Therapeutics Competitors (27)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
TC Biopharm Venture Capital-Backed Glasgow, United Kingdom 00 000.00 0000000000 0 000.00
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
000000000 Corporate Backed or Acquired Culver City, CA 000 00000 000000&0 00000
00000 0000000000 Formerly VC-backed Miramar, FL 00 00000 000000&0 00000
000000 Corporation Paris, France 00 000.00 000000000 000.00
You’re viewing 5 of 27 competitors. Get the full list »

Nohla Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial